In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer

BACKGROUND: New, third-generation aromatase inhibitors (AIs) have proven comparable or superior to the anti-estrogen tamoxifen for treatment of estrogen receptor (ER) and/or progesterone receptor (PR) positive breast cancer. AIs suppress total body and intratumoral estrogen levels. It is unclear whe...

Descripción completa

Detalles Bibliográficos
Autores principales: Lykkesfeldt, Anne E, Henriksen, Katrine L, Rasmussen, Birgitte B, Sasano, Hironobu, Evans, Dean B, Møller, Susanne, Ejlertsen, Bent, Mouridsen, Henning T
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702392/
https://www.ncbi.nlm.nih.gov/pubmed/19531212
http://dx.doi.org/10.1186/1471-2407-9-185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702392/
https://www.ncbi.nlm.nih.gov/pubmed/19531212
http://dx.doi.org/10.1186/1471-2407-9-185

Ejemplares similares